Treatment of Upper Airway Cough Syndrome
For adults with upper airway cough syndrome, initiate empiric treatment with a first-generation antihistamine plus decongestant combination (such as dexbrompheniramine 6 mg or azatadine 1 mg combined with sustained-release pseudoephedrine 120 mg, both twice daily) before pursuing extensive diagnostic workup. 1
Treatment Algorithm Based on Underlying Etiology
When Etiology is Unknown (Empiric Treatment)
Start with first-generation antihistamine/decongestant (A/D) combination therapy immediately. The anticholinergic properties of older antihistamines are critical for efficacy—newer "non-sedating" antihistamines like loratadine and terfenadine have been proven ineffective for this indication 1. Expect improvement within days to 2 weeks 1.
When Allergic Rhinitis is Identified
Choose from multiple effective options:
- Nasal corticosteroids (first-line)
- Nasal cromolyn
- Nasal antihistamines
- Oral leukotriene inhibitors
- Oral antihistamines (non-sedating types work well here, unlike in non-allergic causes)
For allergic rhinitis specifically, non-sedating antihistamines are appropriate because histamine-mediated mechanisms predominate 1.
For Postviral Upper Respiratory Infection or Common Cold
Use first-generation A/D combinations exclusively—the anticholinergic effect is essential for symptom control in non-histamine-mediated UACS 1. If contraindicated (glaucoma, symptomatic benign prostatic hypertrophy), consider ipratropium bromide nasal spray as an alternative 1.
For Chronic Sinusitis
Implement combination therapy for minimum 3 weeks:
- Antibiotic effective against H. influenzae, mouth anaerobes, and S. pneumoniae
- First-generation A/D twice daily for minimum 3 weeks
- Nasal decongestant twice daily for 5 days
- Continue intranasal corticosteroids for 3 months after cough resolution 1
Consider endoscopic sinus surgery only when medical therapy fails and anatomic obstruction is documented 1.
Key Clinical Distinctions
Critical point: The evidence strongly demonstrates that first-generation antihistamines work through anticholinergic mechanisms, not antihistamine effects, in non-allergic UACS 1. This explains why newer antihistamines fail—they lack sufficient anticholinergic activity.
Recent data from Japan suggests nasal corticosteroids alone may be effective for UACS 2, and topical combination therapy (fluticasone nasules, ipratropium bromide, azelastine) showed benefit in a small open study 3, though these approaches require confirmation in larger trials.
Managing Side Effects
To minimize sedation: Start once daily at bedtime for several days before advancing to twice-daily dosing 1. The meta-analysis evidence questions whether first-generation antihistamines truly cause more sedation than "non-sedating" alternatives 1.
Monitor for decongestant complications:
- Insomnia, urinary retention (elderly men)
- Tachycardia, palpitations
- Hypertension exacerbation
- Increased intraocular pressure in glaucoma patients 1
In one controlled trial, only dry mouth and transient dizziness were more common than placebo—no patients discontinued due to adverse effects 1.
Diagnostic Confirmation
UACS is a clinical diagnosis confirmed by treatment response, not by objective findings 1, 4. No pathognomonic signs exist. If empiric A/D therapy fails, obtain sinus imaging before expanding the workup 1. Remember that chronic sinusitis can present with minimal or nonproductive cough without typical acute sinusitis findings 1.
Common Pitfalls
- Do not use newer antihistamines for non-allergic UACS—they are ineffective 1
- Do not delay empiric treatment waiting for diagnostic confirmation 1
- Recognize that endoscopic findings may not correlate with symptom severity 5
- Consider that 26% of patients may experience symptom recurrence even after initial response 6